Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.dragarwal.com | |
Market Cap | 472.07 Cr. | |
Enterprise Value(EV) | 481.29 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 64.07 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 15.68 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 47.03 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 212.09 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 4.74 | Calculated using Price: 1,004.40 |
Dividend Yield | 0.30 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.47 Cr. | 4,700,000 Shares |
FaceValue | 10 | |
Company Profile | ||
Dr.Agarwal's Eye Hospital has been promoted by Dr.J.Agarwal and his family members in 1994. Though the entire family has been in the profession of providing total eye care solutions for almost five decades prior to this, through various private limited company and partnership firms, owned by the family members. The Hospital has always been at the forefront of every medical advancement in the field of Ophthalmic care in the world and has several firsts to its credit. The Hospital is engaged in conducting continuous training and research and development programs and has over a period, developed an excellent team of highly skilled Ophthalmic specialists and surgeons, to assist in its growth plans. |
1 Day |
|
-3.18% |
1 Week |
|
-21.50% |
1 Month |
|
-17.45% |
3 Month |
|
-14.72% |
6 Month |
|
+57.89% |
1 Year |
|
+31.40% |
2 Year |
|
+194.11% |
5 Year |
|
+34.38% |
10 Year |
|
+1042.01% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 14.05 | 26.67 | 0.16 | 27.78 | 21.02 | 29.55 | 26.91 | -2.60 | 36.29 | |
Return on Capital Employed (%) | 16.58 | 18.81 | 7.70 | 28.26 | 31.70 | 34.30 | 39.87 | 16.92 | 42.41 | |
Return on Assets (%) | 3.74 | 8.53 | 0.05 | 8.87 | 7.65 | 11.01 | 9.55 | -0.86 | 9.63 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 19 | 24 | 23 | 29 | 35 | 46 | 56 | 55 | 78 | 95 | |
Non Curr. Liab. | 12 | 13 | 25 | 24 | 24 | 40 | 71 | 42 | 173 | 188 | |
Curr. Liab. | 35 | 31 | 36 | 27 | 37 | 35 | 39 | 70 | 82 | 57 | |
Minority Int. | |||||||||||
Equity & Liab. | 67 | 67 | 84 | 81 | 96 | 120 | 166 | 167 | 333 | 340 | |
Non Curr. Assets | 44 | 44 | 61 | 61 | 73 | 91 | 136 | 123 | 283 | 301 | |
Curr. Assets | 23 | 23 | 24 | 20 | 23 | 30 | 30 | 44 | 50 | 38 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 67 | 67 | 84 | 81 | 96 | 120 | 166 | 167 | 333 | 340 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 113 | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 254 | |
Other Income | 3 | 0 | 0 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | |
Total Income | 116 | 118 | 137 | 150 | 156 | 172 | 179 | 142 | 202 | 256 | |
Total Expenditure | -102 | -103 | -121 | -126 | -129 | -140 | -129 | -110 | -143 | -184 | |
PBIDT | 14 | 15 | 15 | 24 | 27 | 32 | 50 | 32 | 60 | 72 | |
Interest | -4 | -4 | -5 | -4 | -3 | -4 | -9 | -7 | -7 | -7 | |
Depreciation | -6 | -6 | -11 | -9 | -10 | -11 | -21 | -19 | -20 | -24 | |
Taxation | -1 | 0 | 1 | -4 | -7 | -6 | -6 | -7 | -8 | -10 | |
Exceptional Items | |||||||||||
PAT | 2 | 6 | 0 | 7 | 7 | 12 | 14 | -1 | 24 | 30 | |
Adjusted EPS | 5 | 12 | 0 | 16 | 14 | 25 | 29 | -3 | 51 | 64 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 11 | 12 | 14 | 17 | 20 | 19 | 25 | 39 | 34 | 57 | |
Cash Fr. Inv. | -6 | -11 | -10 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | |
Cash Fr. Finan. | -3 | -3 | -5 | 0 | -12 | -8 | 2 | -20 | -8 | -4 | |
Net Change | 2 | -3 | -1 | 0 | 0 | 0 | 2 | 2 | 15 | 7 | |
Cash & Cash Eqvt | 6 | 3 | 1 | 2 | 2 | 2 | 4 | 6 | 22 | 28 |
Sat, 21 Jan 2023
Results- Financial Results For The Quarter And Nine Months Ended December 31 2022 Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that in terms of Regulation 30 33 and other applicable provisions of Listing Regulations the Board of Directors of the Company at its meeting held on January 21 2023 commenced at 12:00 Noon and concluded at 12:45 PM have inter alia approved the Un-audited financial results of the Company for the quarter and nine months ended December 31 2022.1) Copies of the Un-audited Financial Results and Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended December 31 2022 is enclosed.2) The Company has made arrangement for the release of the Un-audited Financial results for the quarter and nine months ended December 31 2022 in the newspaper as per the requirement of the Listing Regulations |
Sat, 21 Jan 2023
Board Meeting Outcome for Unaudited Financial Results And Limited Review Report For The Quarter And Nine Months Ended December 31 2022- Outcome Of The Board Meeting Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that in terms of Regulation 30 33 and other applicable provisions of Listing Regulations the Board of Directors of the Company at its meeting held on January 21 2023 commenced at 12:00 Noon and concluded at 12:45 PM have inter alia approved the Un-audited financial results of the Company for the quarter and nine months ended December 31 2022.1) Copies of the Un-audited Financial Results and Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended December 31 2022 is enclosed.2) The Company has made arrangement for release of the Un-audited Financial results for the quarter and nine months ended December 31 2022 in the newspaper as per the requirement of the Listing Regulations. |
Wed, 18 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Disclosure under Regulation 39(3) of the SEBI (LODR) Regulations 2015 for the issue of duplicate share certificates is submitted. |
Fri, 27 Jan 2023 |
|
|
|
|
|